Wall Street is hovering around record highs as a couple of high-profile companies reported their latest quarterly earnings.
The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure (HF) or death from any cause among patients with an increased risk for HF following acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results